Knight Lea Daniels
Known title: EVP & CFOCIK: 0001983748
Associated companies
Transaction History
| IART | ▼ Sell | Tax Withholding | 5,226 | $94K | 7/3/2026 | View on chart |
| IART | ▼ Sell | Tax Withholding | 8,089 | $78K | 3/11/2026 | View on chart |
| IART | ▼ Sell | Tax Withholding | 2,561 | $35K | 7/3/2025 | View on chart |
| IART | ▼ Sell | Tax Withholding | 1,655 | $40K | 3/11/2025 | View on chart |
| IART | ▲ Buy | Grant | 20,859 | $0 | 3/11/2025 | View on chart |
| IART | ▼ Sell | Tax Withholding | 2,561 | $74K | 7/3/2024 | View on chart |
| IART | ▲ Buy | Grant | 11,822 | $0 | 3/11/2024 | View on chart |
| IART | ▲ Buy | Grant | 8,283 | $0 | 3/11/2024 | View on chart |
| IART | ▲ Buy | Grant | 18,293 | $0 | 7/3/2023 | View on chart |
| IART | ▲ Buy | Grant | 6,098 | $0 | 7/3/2023 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 17, 2026
Integra Focuses on ENT Portfolio; Analyst Target Cut to $15
Integra LifeSciences will showcase its ENT and instrument lines and sponsor new clinical research presentations at the AAO‑HNSF 2026 meeting. A recent analyst review lowered the price target to $15, reflecting a more cautious outlook. The company’s focus on ENT products comes amid a broader discussion of healthcare stocks that are of concern to investors.
Integra Focuses on ENT Portfolio; Analyst Target Cut to $15. Integra LifeSciences will showcase its ENT and instrument lines and sponsor new clinical research presentations at the AAO‑HNSF 2026 meeting. A recent analyst review lowered the price target to $15, reflecting a more cautious outlook. The company’s focus on ENT products comes amid a broader discussion of healthcare stocks that are of concern to investors.